SCHEMBL24035985

SCHEMBL24035985

CC(C)(O)c1cc(C(=O)O)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 6/20 0.53
GLRA3 O75311 1/20 0.38
GLRB P48167 1/20 0.38
TPMT P51580 1/20 0.35
RXRA P19793 3/20 0.34
RXRB P28702 3/20 0.34
RXRG P48443 2/20 0.34
ACE2 Q9BYF1 1/20 0.34
RARB P10826 1/20 0.34
RARG P13631 1/20 0.34
SRD5A2 P31213 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
HCAR3 P49019 1/20 0.33
NR4A1 P22736 1/20 0.32
NOTUM Q6P988 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14329503 0.86 DAO (0.55) DAOGLRA3GLRBTPMTRXRA
SCHEMBL24035984 0.79 DAO (0.48) DAOGLRA3GLRBTPMTRXRA
SCHEMBL3942343 0.78 DAO (0.47) DAOGLRA3GLRBTPMTRXRA
SCHEMBL21986753 0.78 DAO (0.50) DAORXRARXRBRXRGSRD5A2
SCHEMBL24036273 0.75 DAO (0.45) DAOGLRA3GLRBTPMTCA12
SCHEMBL29361570 0.74 DAO (0.47) DAORXRARXRBRXRGSRD5A2
SCHEMBL21128627 0.73 DAO (0.46) DAORARBCA2TP53TSHR
SCHEMBL131281 0.70
SCHEMBL9414397 0.70 TYR (0.30)
SCHEMBL132181 0.70 ESR1 (0.41) DAOCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed
WO-2021231474-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS DAO 3281/4885GLRA3 3453/4885GLRB 3068/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS DAO 3281/4885GLRA3 3453/4885GLRB 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.